Innovent Biologics said it entered an exclusive agreement with Daiichi Sankyo to commercialize VANFLYTA (quizartinib) in China, effective August 9, 2026. The deal is a positive commercial development for the product’s China launch, though the announcement provides limited financial terms to gauge magnitude for near-term earnings impact.
Innovent Biologics said it entered an exclusive agreement with Daiichi Sankyo to commercialize VANFLYTA (quizartinib) in China, effective August 9, 2026. The deal is a positive commercial development for the product’s China launch, though the announcement provides limited financial terms to gauge magnitude for near-term earnings impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
